A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)
Completed · Phase 2
Conditions studied: Non Small Cell Lung Cancer Metastatic
In brief
This is a multicenter, single arm, open label phase II study in treatment-naïve for advanced stage of the disease and immunotherapy-naïve patients with advanced non-squamous NSCLC and with \< 50% of tumor cells expressing programmed death-ligand 1 (PD-L1) by immunohistochemical (IHC) staining.
Key facts
- Study ID
- NCT03353675
- Run by
- Transgene
- People needed
- 44
- Starts
- 2018-01-05
- Expected to finish
- 2021-02-17
- Last updated by the study team
- 2022-01-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Charlotte — Charlotte, North Carolina, United States
- Nashville — Nashville, Tennessee, United States
- Libramont — Libramont, Belgium
- Créteil — Créteil, France
- Mulhouse — Mulhouse, France
- Rennes — Rennes, France
- Strasbourg — Strasbourg, France
- Budapest — Budapest, Hungary
- Szekesfehervar — Székesfehérvár, Hungary
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.